Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
It is a single-center, single-arm Phase II clinical study. This clinical trial aimed to
evaluate the PFS of imatinib combined with toripalimab in stage III unresectable and stage IV
melanoma with CKIT gene mutation.